英夫利西单抗在炎症性肠病中的应用：现状与展望
Application of Infliximab in Inflammatory Bowel Disease: Current Status and Prospects
DOI: 10.12677/ACM.2022.122139, PDF,   
作者: 李彦琴：西安医学院，陕西 西安；刘丹平：陕西省人民医院，陕西 西安
关键词: 英夫利西单抗；炎症性肠病；克罗恩病；溃疡性结肠炎；Infliximab； Inflammatory Bowel Disease； Crohn’s Disease； Ulcerative Colitis
摘要: 炎症性肠病(inflammatory bowel disease, IBD)是一组病因及发病机制至今尚未完全清楚的慢性非特异性肠道炎症性疾病，包括溃疡性结肠炎(ulcerative colitis, UC)、克罗恩病(Crohn disease, CD)和未分类IBD (IBD-unclassified, IBD-U)，对胃肠道造成严重损害。近几年生物制剂开始广泛应用于IBD的治疗，特别是英夫利西单抗(infliximab, IFX)常用于成人及儿童IBD患者，因此在此综述中我们将重点关注IFX在IBD中的应用，并对IFX在治疗IBD领域的最新和未来发展进行概述。
Abstract: Inflammatory bowel disease (IBD) is a group of chronic non-specific inflammatory bowel diseases with unknown etiology and pathogenesis. These include ulcerative colitis (UC), Crohn disease (CD), and IBD-Unclassified (IBD-U), which causes severe damage to the gastrointestinal tract. In recent years, biologics have been widely used in the treatment of IBD, especially infliximab (IFX), which is commonly used in adults and children with IBD. Therefore, in this review, we will focus on the application of IFX in IBD, and summarize the latest and future development of IFX in the treatment of IBD.
文章引用：李彦琴, 刘丹平. 英夫利西单抗在炎症性肠病中的应用：现状与展望[J]. 临床医学进展, 2022, 12(2): 952-958. https://doi.org/10.12677/ACM.2022.122139

参考文献

[1] Hodson, R. (2016) Inflammatory Bowel Disease. Nature, 540, S97. [Google Scholar] [CrossRef] 
[2] Däbritz, J., Gerner, P., Enninger, A., Claßen, M. and Radke, M. (2017) Inflammatory Bowel Disease in Childhood and Adolescence. Deutsches Ärzteblatt International, 114, 331-338. [Google Scholar] [CrossRef] [PubMed]
[3] Dipasquale, V. and Romano, C. (2020) Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease: Efficacy, Immunogenicity and Safety. Journal of Clinical Pharmacy and Therapeutics, 45, 1228-1234. [Google Scholar] [CrossRef] [PubMed]
[4] Seyedian, S.S., Nokhostin, F. and Malamir, M.D. (2019) A Review of the Diagnosis, Prevention, and Treatment Methods of Inflammatory Bowel Disease. Journal of Medicine and Life, 12, 113-122.
[5] Zhou, Q., Shen, Z.F., Wu, B.S., Xu, C.B., He, Z.Q., Chen, T., et al. (2019) Risk of Colorectal Cancer in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice, 2019, Article ID: 5363261.[CrossRef] [PubMed]
[6] Corica, D. and Romano, C. (2017) Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review. Journal of Clinical Gastroenterology, 51, 100-110. [Google Scholar] [CrossRef] 
[7] Chouliaras, G., Margoni, D., Dimakou, K., Fessatou, S., Panayiotou, I. and Roma-Giannikou, E. (2017) Disease Impact on the Quality of Life of Children with Inflammatory Bowel Disease. World Journal of Gastroenterology, 23, 1067-1075.[CrossRef] [PubMed]
[8] Melsheimer, R., Geldhof, A., Apaolaza, I. and Schaible, T. (2019) Remicade® (Infliximab): 20 Years of Contributions to Science and Medicine. Biologics, 13, 139-178. [Google Scholar] [CrossRef] 
[9] de Vries, H.S., Van Oijen, M.G.H., Driessen, R.J.B., De Jong, E.M.G.J., Creemers, M.C.W., Kievit, W., et al. (2011) Appropriate Infliximab Infusion Dosage and Monitoring: Results of a Panel Meeting of Rheumatologists, Dermatologists and Gastroenterologists. British Journal of Clinical Pharmacology, 71, 7-19.[CrossRef] [PubMed]
[10] Cilag, A.G. 注射用英夫利西单抗说明书[Z]. 核准日期: 2007-02-15; 修改日期: 2021-06-16.
https://www.xian janssen.com.cn/sites/default/files/PDF/40. zhu_she_yong_ying_fu_li_xi_dan_kang_ni_yin_ zhi_ban_shuo_ming_shu_.pdf
[11] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018年·北京) [J]. 中华炎性肠病杂志(中英文), 2018, 2(3): 173-190.
[12] 中华医学会儿科学分会消化学组, 中华医学会儿科学分会临床营养学组. 儿童炎症性肠病诊断和治疗专家共识[J]. 中华儿科杂志, 2019, 57(7): 501-507.
[13] Harbord, M., Annese, V., Vavricka, S.R., Allez, M., Barreiro-de Acosta, M., Boberg, K.M., et al. (2016) The First European Evidence-Based Consensus on Extra-Intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis, 10, 239-254. [Google Scholar] [CrossRef] [PubMed]
[14] Gionchetti, P., Dignass, A., Danese, S., Magro Dias, F.J., Rogler, G., Lakatos, P.L., et al. (2017) 3rd European Evidence-Based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations. Journal of Crohn’s and Colitis, 11, 135-149.[CrossRef] [PubMed]
[15] Hemperly, A. and Vande Casteele, N. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics, 57, 929-942. [Google Scholar] [CrossRef] [PubMed]
[16] 李玥, 钱家鸣. 抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017) [J]. 协和医学杂志, 2017(Z2): 239-243.
[17] Wong, U. and Cross, R.K. (2017) Primary and Secondary Nonresponse to Infliximab: Mechanisms and Countermeasures. Expert Opinion on Drug Metabolism & Toxicology, 13, 1039-1046. [Google Scholar] [CrossRef] [PubMed]
[18] Shivaji, U.N., Sharratt, C.L., Thomas, T., Smith, S.C.L., Iacucci, M., Moran, G.W., et al. (2019) Review Article: Managing the Adverse Events Caused by Anti-TNF Therapy in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics, 49, 664-680. [Google Scholar] [CrossRef] [PubMed]
[19] 中国炎症性肠病诊疗质控评估中心, 中华医学会消化病学分会炎症性肠病学组. 生物制剂治疗炎症性肠病专家建议意见[J]. 中华消化杂志, 2021, 41(6): 366-378.
[20] D’Haens, G.R. and van Deventer, S. (2021) 25 Years of Anti-TNF Treatment for Inflammatory Bowel Disease: Lessons from the Past and a Look to the Future. Gut, 70, 1396-1405. [Google Scholar] [CrossRef] [PubMed]
[21] Jongsma, M.M.E., Aardoom, M.A., Cozijnsen, M.A., van Pieterson, M., de Meij, T., Groeneweg, M., et al. (2022) First-Line Treatment with Infliximab versus Conventional Treatment in Children with Newly Diagnosed Moderate-to-Severe Crohn’s Disease: An Open-Label Multicentre Randomised Controlled Trial. Gut, 71, 34-42. [Google Scholar] [CrossRef] [PubMed]
[22] Reenaers, C., Mary, J.Y., Nachury, M., Bouhnik, Y., Laharie, D., Allez, M., et al. (2018) Outcomes 7 Years after Infliximab Withdrawal for Patients with Crohn’s Disease in Sustained Remission. Clinical Gastroenterology and Hepatology, 16, 234-243.e2. [Google Scholar] [CrossRef] [PubMed]
[23] Qiu, Y., Chen, B.L., Mao, R., Zhang, S.H., He, Y., Zeng, Z.R., et al. (2017) Systematic Review with Meta-Analysis: Loss of Response and Requirement of Anti-TNFα Dose Intensification in Crohn’s Disease. Journal of Gastroenterology, 52, 535-554. [Google Scholar] [CrossRef] [PubMed]
[24] Olsen, T., Goll, R., Cui, G., Christiansen, I. and Florholmen, J. (2009) TNF-Alpha Gene Expression in Colorectal Mucosa as a Predictor of Remission after Induction Therapy with Infliximab in Ulcerative Colitis. Cytokine, 46, 222-227. [Google Scholar] [CrossRef] [PubMed]
[25] Ordás, I., Mould, D.R., Feagan, B.G. and Sandborn, W.J. (2012) Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms. Clinical Pharmacology & Therapeutics, 91, 635-466. [Google Scholar] [CrossRef] [PubMed]
[26] Brandse, J.F., Mathôt, R.A., van der Kleij, D., Rispens, T., Ashruf, Y., Jansen, J.M., et al. (2016) Pharmacokinetic Features and Presence of Antidrug Antibodies Associate with Response to Infliximab Induction Therapy in Patients with Moderate to Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 14, 251-258.e1-2. [Google Scholar] [CrossRef] [PubMed]
[27] Lamb, C.A., Kennedy, N.A., Raine, T., Hendy, P.A., Smith, P.J., Limdi, J.K., et al. (2019) British Society of Gastroenterology Consensus Guidelines on the Management of Inflammatory Bowel Disease in Adults. Gut, 68, s1-s106. [Google Scholar] [CrossRef] [PubMed]

为你推荐